| Title |
Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients
|
|---|---|
| Published in |
International Journal of Clinical Pharmacy, May 2015
|
| DOI | 10.1007/s11096-015-0077-4 |
| Pubmed ID | |
| Authors |
Barbara O. M. Claus, Sylvia Snauwaert, Filomeen Haerynck, Sabine Van Daele, Frans De Baets, Petra Schelstraete |
| Abstract |
Case description The use of i.v. colistin reappeared recently for the treatment of multidrug-resistant Gram negative organisms in the intensive care and cystic fibrosis (CF) setting. According to the latest pharmacokinetic data, a loading dose and high antibiotic doses are given. Two cases of adverse events (paraesthesias, bad taste) were observed immediately after the start of infusion of a high dose of i.v. colistin in adult CF patients at the Ghent University Hospital. Conclusion Recommendations for optimal administration of i.v. colistin in adult CF patients are scarce. This article highlights the importance of mode of administration to avoid toxicity and relates it to recent pharmacokinetic/-dynamic literature. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 6% |
| Unknown | 15 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 19% |
| Student > Master | 3 | 19% |
| Other | 2 | 13% |
| Student > Postgraduate | 2 | 13% |
| Researcher | 2 | 13% |
| Other | 2 | 13% |
| Unknown | 2 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 31% |
| Agricultural and Biological Sciences | 2 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
| Nursing and Health Professions | 1 | 6% |
| Social Sciences | 1 | 6% |
| Other | 3 | 19% |
| Unknown | 2 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2015.
All research outputs
#18,411,569
of 22,807,037 outputs
Outputs from International Journal of Clinical Pharmacy
#874
of 1,079 outputs
Outputs of similar age
#193,612
of 267,813 outputs
Outputs of similar age from International Journal of Clinical Pharmacy
#23
of 25 outputs
Altmetric has tracked 22,807,037 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,079 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,813 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.